CymaBay Therapeutics Inc. (NASDAQ:CBAY) shares traded up 4.6% on Monday . The stock traded as high as $2.05 and last traded at $2.03, with a volume of 248,226 shares changing hands. The stock had previously closed at $1.94.

Several research analysts recently weighed in on the company. HC Wainwright cut CymaBay Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the company from $6.00 to $2.25 in a research report on Wednesday, June 1st. Zacks Investment Research cut CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 31st. Finally, Roth Capital assumed coverage on CymaBay Therapeutics in a research report on Friday, July 1st. They set a “buy” rating for the company.

The company’s market capitalization is $53.93 million. The firm’s 50-day moving average is $1.77 and its 200 day moving average is $1.75.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.02. On average, equities analysts predict that CymaBay Therapeutics Inc. will post ($1.21) EPS for the current year.

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.